Rachel Wade

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

Daniel Catovsky, Estella Matutes, R. F. Bezares et al. · The Lancet · 2007 · 679 citations

Medicine, Oncology, Pharmacology +13

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Rachel Wade et al. · The Lancet Oncology · 2013 · 483 citations · Full text

Medicine, Hematology, Oncology +16

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Chris Mitchell et al. · The Lancet Oncology · 2014 · 305 citations · Full text

Medicine, Oncology, Pediatrics +13

Mutational Status of the <i>TP53</i> Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

David González de Castro, Pilar Martı́nez, Rachel Wade et al. · Journal of Clinical Oncology · 2011 · 267 citations

Medicine, Molecular Genetics, Oncology +11

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003

David O’Connor, Jessica Bate, Rachel Wade et al. · Blood · 2014 · 251 citations

Medicine, Infectious Diseases, Pediatrics +16